Protara Therapeutics, Inc. Interest and Other Income
Protara Therapeutics, Inc. (TARA) reported Interest and Other Income of $1.66 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Income Statement › Other Income
us-gaap:InterestAndOtherIncome · last filed 2026-05-13
- Protara Therapeutics, Inc. interest and other income for the quarter ending 2026-03-31 was $1.66M, a 6.50% increase year-over-year.
- Protara Therapeutics, Inc. interest and other income for the quarter ending 2025-12-31 was $1.19M, a 38.34% increase year-over-year.
- Protara Therapeutics, Inc. interest and other income for the quarter ending 2025-09-30 was $1.06M, a 60.55% increase year-over-year.
- Protara Therapeutics, Inc. interest and other income for the quarter ending 2025-06-30 was $1.22M, a 8.23% increase year-over-year.
- Protara Therapeutics, Inc. interest and other income for fiscal 2025 was $5.02M, a 51.02% increase from fiscal 2024.
- Protara Therapeutics, Inc. interest and other income for fiscal 2024 was $3.33M, a 21.97% increase from fiscal 2023.
- Protara Therapeutics, Inc. interest and other income for fiscal 2023 was $2.73M.
| Period end | Interest and Other Income 3 month | Interest and Other Income 6 month | Interest and Other Income 9 month | Interest and Other Income 12 month |
|---|---|---|---|---|
| 2026-03-31 | $1.66M 10-Q · filed 2026-05-13 | $2.84M derived: sum of 2 quarters · filed 2026-05-13 | $3.90M derived: sum of 3 quarters · filed 2026-05-13 | $5.12M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.25M derived: sum of 2 quarters · filed 2026-03-10 | $3.47M derived: sum of 3 quarters · filed 2026-03-10 | $5.02M 10-K · filed 2026-03-10 |
| 2025-09-30 | $1.06M 10-Q · filed 2025-11-10 | $2.28M derived: sum of 2 quarters · filed 2025-11-10 | $3.84M 10-Q · filed 2025-11-10 | $4.69M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-06-30 | $1.22M 10-Q · filed 2025-08-11 | $2.78M 10-Q · filed 2025-08-11 | $3.64M derived: sum of 3 quarters · filed 2026-05-13 | $4.29M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-03-31 | $1.55M 10-Q · filed 2026-05-13 | $2.41M derived: sum of 2 quarters · filed 2026-05-13 | $3.07M derived: sum of 3 quarters · filed 2026-05-13 | $4.20M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $858.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $1.52M derived: sum of 2 quarters · filed 2026-03-10 | $2.65M derived: sum of 3 quarters · filed 2026-03-10 | $3.33M 10-K · filed 2026-03-10 |
| 2024-09-30 | $659.00K 10-Q · filed 2025-11-10 | $1.79M derived: sum of 2 quarters · filed 2025-11-10 | $2.47M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $1.13M 10-Q · filed 2025-08-11 | $1.81M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $679.00K 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $2.73M 10-K · filed 2025-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |